查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
心血管和软组织修復贴片市场——增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1190228

心血管和软组织修復贴片市场——增长、趋势、COVID-19 影响和预测 (2023-2028)

Cardiovascular and Soft Tissue Repair Patches Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

心血管和软组织修復贴片市场预计在预测期内的复合年增长率为 8%。

COVID-19 大流行的早期阶段对市场产生了重大影响，因为严格的封锁和政府限制减缓了 COVID-19 的传播。 结果，临床程序的数量减少了。 在大流行期间，由于封锁规定，人们没有去医院和诊所接受心血管护理。 根据 2021 年 5 月发表在 PubMed 上的一篇文章，在英国进行的一项研究发现，在 COVID-19 大流行期间，英格兰各地的心臟手术数量显着下降，超过 45,000 例手术出现赤字。研究表明，大多数心臟手术不是在大流行期间进行的，这可能会影响长期的发病率和死亡率。 根据 2022 年 3 月发表在 PubMed Central 上的一篇论文，美国的一项研究表明，在大流行期间，成年人的心臟手术量显着减少。 而且，根据 2021 年 9 月在 PubMed Central 上发表的一篇论文，在大流行后重新开放期间观察到住院和心血管手术未完全恢復到激增前的水平，但最终 COVID-19-预计将恢復到或超过 19 岁之前的水平。 因此，COVID-19 爆发对其前身的市场增长产生了负面影响。 目前，随着大流行的消退，市场正在获得牵引力，预计在本研究的预测期内将稳定增长。

此外，技术进步、先天性心脏病患病率增加以及研发支出增加是推动市场增长的因素。 此外，先天性心房和室间隔缺损患病率的上升以及微创手术的上升趋势也导致贴片的广泛采用，引发了市场增长。 此外，先天性膈疝和腹股沟疝的日益流行也推动了市场增长，因为这些贴片用于通过组织修復程序治疗这些疾病。 NCBI 2022 年 8 月的数据表明，腹股沟疝会影响大约 25% 的男性和不到 2% 的女性，其中男性约占腹股沟疝病例的 90%。 预计腹股沟疝患病率的增加将导致软组织修復贴片的使用增加。 此外，製造商和研究机构之间加强合作、政府与心臟治疗相关的举措以及新技术的开发是推动心血管和软组织修復贴片市场增长的其他因素。 然而，严格的监管框架可能会阻碍市场增长。

主要市场趋势

推测软组织修復部分未来会健康成长。

由于各种疝气的患病率不断上升，软组织修復被认为代表了未来的健康成长。 疝气是一种肠道或脂肪组织从腹部的薄弱部位突出的疾病。 软组织修復补丁有助于治疗疝气疾病。 根据 PubMed 于 2022 年 4 月发表的一篇论文，埃塞俄比亚的一项研究表明外翻疝的总体患病率很高。 年龄大、便秘、长期咳嗽、提重物是导致疝气外翻的主要原因。 此外，根据 PubMed Central 于 2021 年 8 月发表的一篇论文，在沙特阿拉伯对 500 名参与者进行的横断面研究中，18-25 岁的参与者中腹疝的患病率为 38.8%。患病率为21.2%。

市场主要参与者的重大发展对该细分市场的增长产生了积极影响。 例如，2021 年 7 月，全球医疗技术巨头 BD（Becton, Dickinson and Company）宣布收购 Tepha, Inc.，以推进软组织修復和再生方面的新创新。

因此，由于上述因素，预计软组织修復领域在预测期内将出现显着增长。

北美主导着心血管和软组织修復市场

由于心脏病患病率上升、大量製药公司的存在、研发支出增加以及疝病发病率增加，北美是全球心血管和软组织修復补片市场中的一个大市场。预计一份。 例如，根据美国疾病控制与预防中心 2022 年 7 月的数据，心脏病是美国的主要死因之一。 据说在美国每34秒就有一个人死亡。 冠心病是最常见的心脏病，在美国影响着大约 2010 万 20 岁及以上的成年人。

大量产品发布、市场参与者高度集中以及製造商在美国的存在是推动该国脱毛设备市场增长的一些因素。 例如，2020年2月，总部位于奥克兰的私营软组织修復公司Aroa Biosurgery在美国市场推出了一款用于软组织修復和重建的新产品Myriad。 预计在该地区持续推出此类产品将推动该国的市场增长。

因此，由于上述因素，北美市场有望扩大。

竞争格局

心血管和软组织修復贴片市场竞争适中，由几家大型企业组成。 目前主导市场的公司包括 Anteris、LeMaitre Vascular Inc.、Baxter、Cryolife, Inc、CorMatrix, Inc、Abbott (St Jude Medical)、B. Braun Melsungen AG、Terumo Medical Corporation、Integra LifeSciences Corporation、Glycar，例如，SA Pty有限公司

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 调查先决条件
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 技术进步
    • 先天性心脏病增加
    • 研发费用增加
  • 市场製约因素
    • 监管框架
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按原材料
    • 生物材料和组织工程材料
    • 膨体聚四氟乙烯
    • 其他
  • 通过使用
    • 心臟修復
    • 软组织修復
    • 血管修復和重建
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Anteris
    • LeMaitre Vascular Inc.
    • Baxter
    • Cryolife, Inc.
    • CorMatrix, Inc
    • Abbott（St Jude Medical）
    • B. Braun Melsungen AG
    • Terumo Medical Corporation
    • Integra LifeSciences Corporation
    • Glycar SA Pty Ltd.

第7章 市场机会今后动向

简介目录
Product Code: 69708

The Cardiovascular and Soft Tissue Repair Patches Market is expected to register a CAGR of 8% during the forecast period.

The early phase of the COVID-19 pandemic significantly impacted the market, as the strict lockdowns and government regulations slowed the spread of COVID-19. This resulted in a reduction in the number of clinical procedures. During the pandemic, people did not visit hospitals or clinics for cardiovascular procedures due to lockdown restrictions. According to an article published by PubMed in May 2021, a study performed in United Kingdom showed that the number of cardiac procedures has significantly declined across England during the COVID-19 pandemic, with a deficit of more than 45,000 procedures, without an increase in the risk of mortality for most cardiac procedures were not performed during the pandemic, and this might impact long-term morbidity and mortality. Also, according to an article published by PubMed Central in March 2022, a study in United States showed that the adult cardiac surgery volume decreased significantly during the pandemic. And, according to an article published by PubMed Central in September 2021, in the reopening phase after the pandemic an incomplete recovery to pre-surge levels of hospitalizations and cardiovascular procedures was observed, but it is expected to eventually rebound to meet or exceed pre-COVID-19 levels. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; currently, the market has gained traction as the pandemic has subsided, and it is expected to have a stable growth during the forecast period of the study.

Further, the increasing technological advancements, increasing prevalence of congenital heart diseases, and increasing R&D expenditure attribute to the growth of the market. In addition, the rising prevalence of congenital atrial and ventricular septal defects and growing inclination towards minimally invasive procedures also result in high adoption of the patches and trigger the growth of the market. Moreover, an increase in the prevalence of congenital diaphragmatic hernias, and inguinal hernias is also promoting the growth of the market as these patches are used in the treatment of these disorders through tissue repairing procedures. As per the data by NCBI in August 2022, inguinal hernia affects nearly 25% of men and less than 2% of women over their lifetime, and males account for about 90% of all inguinal hernia cases. The increasing prevalence of inguinal hernia is expected to increase the usage of soft tissue repair patches. Furthermore, increasing collaboration between manufacturers and research organizations, government initiatives associated with cardiac treatments, and the development of novel technologies are a few more factors driving the growth of the cardiovascular and soft tissue repair patches market. However, the stringent regulatory framework is likely to impede market growth.

Key Market Trends

Soft Tissue Repair Segment is Estimated to Witness a Healthy Growth in Future.

Soft tissue repair is estimated to witness healthy growth in the future, attributed to the increasing prevalence of various types of hernias. A hernia is a disorder in which the intestine or fatty tissue protrudes through a weaker portion of the abdomen. Soft tissue repair patches help in treating hernia disorder. According to an article published by PubMed in April 2022, a study in Ethiopia showed that the overall prevalence of external hernia was high in the country. Old age, constipation, chronic cough, and lifting heavy objects were some major reasons behind external hernias. Furthermore, according to the article published by PubMed Central in August 2021, a cross-sectional study was performed on 500 participants in Saudi Arabia, which showed that the prevalence of abdominal hernia was 38.8 percent and the participants in 18-25 years had less prevalence of 21.2 percent.

Key developments by major players in the market are positively affecting the growth of the segment. For instance, in July 2021, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that they had acquired Tepha, Inc., to drive new innovations in soft tissue repair and generation.

Therefore, the soft tissue repair segment is expected to witness significant growth over the forecast period due to the abovementioned factors.

North America is Dominating the Cardiovascular and Soft Tissues Repair Market

North America is expected to hold a significant market share in the global Cardiovascular and Soft Tissue Repair Patches Market due to the rising prevalence of cardiac diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, and increasing incidences of hernia disorders. For instance, according to data from the Centers for Disease Control and Prevention in July 2022, heart disease is one of the leading causes of death in United States. It is estimated that one person dies every 34 seconds in United States. Among all the heart diseases coronary heart disease is the most common type of heart disease and about 20.1 million adults age 20 and older have coronary heart disease in United States.

Key product launches, high concentration of market players, and manufacturers' presence in United States are some of the factors driving the growth of the hair removal devices market in the country. For instance, in February 2020, Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, launched Myriad, a new product for soft tissue repair and reconstruction, in United States market. These continuous product launches in the region are anticipated to drive the growth of the market in the country.

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North American region.

Competitive Landscape

The Cardiovascular and Soft Tissue Repair Patches Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Anteris, LeMaitre Vascular Inc., Baxter, Cryolife, Inc., CorMatrix, Inc, Abbott (St Jude Medical), B. Braun Melsungen AG, Terumo Medical Corporation, Integra LifeSciences Corporation, and Glycar SA Pty Ltd among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements
    • 4.2.2 Increasing Prevalence of Congenital Heart Diseases
    • 4.2.3 Increasing R&D Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Framework
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Raw Material
    • 5.1.1 Biomaterial and Tissue Engineered Material
    • 5.1.2 ePTFE
    • 5.1.3 Others
  • 5.2 By Application
    • 5.2.1 Cardiac Repair
    • 5.2.2 Soft Tissue Repair
    • 5.2.3 Vascular Repair & Reconstruction
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anteris
    • 6.1.2 LeMaitre Vascular Inc.
    • 6.1.3 Baxter
    • 6.1.4 Cryolife, Inc.
    • 6.1.5 CorMatrix, Inc
    • 6.1.6 Abbott (St Jude Medical)
    • 6.1.7 B. Braun Melsungen AG
    • 6.1.8 Terumo Medical Corporation
    • 6.1.9 Integra LifeSciences Corporation
    • 6.1.10 Glycar SA Pty Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS